Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma

Colin Thomas; Sameep Thapa; Connor McLaughlin; Molly Halloran; Pierluigi Porcu

doi:10.3389/fonc.2022.1098375

Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma

Colin Thomas
, Sameep Thapa
, Connor McLaughlin
, Molly Halloran
, Pierluigi Porcu

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Original language	English
Article number	1098375
Journal	Frontiers in Oncology
Volume	12
DOIs	https://doi.org/10.3389/fonc.2022.1098375
State	Published - Jan 4 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

R-CHOP
diffuse large B cell lymphoma
front-line
polatuzumab vedotin
treatment

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3389/fonc.2022.1098375

Cite this

@article{20d8de14703249eeb80b500549e8eb2b,

title = "Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma",

keywords = "R-CHOP, diffuse large B cell lymphoma, front-line, polatuzumab vedotin, treatment",

author = "Colin Thomas and Sameep Thapa and Connor McLaughlin and Molly Halloran and Pierluigi Porcu",

year = "2023",

month = jan,

day = "4",

doi = "10.3389/fonc.2022.1098375",

language = "English",

volume = "12",

}

TY - JOUR

T1 - Point and counterpoint

T2 - Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma

AU - Thomas, Colin

AU - Thapa, Sameep

AU - McLaughlin, Connor

AU - Halloran, Molly

AU - Porcu, Pierluigi

PY - 2023/1/4

Y1 - 2023/1/4

KW - R-CHOP

KW - diffuse large B cell lymphoma

KW - front-line

KW - polatuzumab vedotin

KW - treatment

UR - https://www.scopus.com/pages/publications/85146802540

UR - https://www.scopus.com/pages/publications/85146802540#tab=citedBy

U2 - 10.3389/fonc.2022.1098375

DO - 10.3389/fonc.2022.1098375

M3 - Article

AN - SCOPUS:85146802540

SN - 2234-943X

VL - 12

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 1098375

ER -

Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this